Skip to main content
Premium Trial:

Request an Annual Quote

Inching Toward Acquisition by ViroLogic, Aclara Posts 34-Percent Decline in Q3 Revenue

NEW YORK, Nov. 9 (GenomeWeb News) - Aclara today reported a 34-percent decline in third-quarter revenue as costs for its impending acquisition by ViroLogic helped widen net losses.


Total receipts for the three months ended Sept. 30 fell to $181,000 from $276,000 year over year.


The company, which is slated to be acquired by VioroLogic during the fourth quarter, said net losses for the period fell to $4 million, or $.11 per share, from $4.9 million, or $.14 per share, year over year.


As GenomeWeb News reported in June, Aclara said it would be acquired by ViroLogic for around $180 million in order to develop and commercialize Aclara's eTag assays for molecular diagnostic applications. The new company will be called ViroLogic.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.